Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database
Alzheimer s & DementiaPublished 2 September 2010
Kaori Ito, Brian Corrigan, Qinying Zhao, Jonathan French, Raymond Miller, Holly Soares
Citations140
SJR quartileQ1
SJR score3.60
SNIP2.90
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
A mathematical model was developed to describe the longitudinal response in Alzheimer's Disease Assessment Scale‐cognitive (ADAS‐cog) obtained from the Alzheimer's disease Neuroimaging Initiative.
Abstract
BACKGROUND: A mathematical model was developed to describe the longitudinal response in Alzheimer's Disease Assessment Scale-cognitive (ADAS-cog) obtained from the Alzheimer's Disease Neuroimaging Initiative. METHODS: The model was fit to the longitudinal ADAS-cog scores from 817 patients. Risk factors (age, apolipoprotein ɛ4 [APOE ɛ4] genotype, gender, family history of AD, years of education) and baseline severity were tested as covariates. RESULTS: Rate of disease progression increased with baseline severity. Age, APOE ɛ4 genotype, and gender were identified as potential covariates influencing disease progression. The rate of disease progression in patients with mild to moderate AD was estimated as approximately 5.5 points/yr. CONCLUSIONS: A disease progression model adequately described the natural decline of ADAS-cog observed in Alzheimer's Disease Neuroimaging Initiative. Baseline severity is an important covariate to predict a curvilinear rate of disease progression in normal elderly, mild cognitive impairment, and AD patients. Age, APOE ɛ4 genotype, and gender also influence the rate of disease progression.
Keywords
Medicine
The Lancet NeurologyHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
4,772 Citations2009Clifford R. Jack, David S. Knopman +6 more
This work proposes a model that relates disease stage to AD biomarkers in which Abeta biomarkers become abnormal first, before neurodegenerative biomarkers and cognitive symptoms, and neurodegnerative biomarker become abnormal later, and correlate with clinical symptom severity.
Archives of NeurologyMild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials
961 Citations2004Michael Grundman
Patients with MCI had a predominant memory impairment with relative sparing of other cognitive domains and were intermediate between clinically normal individuals and patients with AD on cognitive and functional ratings.
Alzheimer Disease & Associated DisordersCognitive Reserve and Alzheimer Disease
823 Citations2006Yaakov Stern
Because CR may modulate the clinical expression of AD pathology, it is an important consideration in studies of “preclinical” AD and treatment studies, and there is also the possibility that directly enhancing CR may help forestall the diagnosis of AD.
Archives of General PsychiatryThe Relationships Between Age, Sex, and the Incidence of Dementia and Alzheimer Disease
762 Citations1998Sujuan Gao, Hugh C. Hendrie +2 more
NeurologyVascular risk factors, incidence of MCI, and rates of progression to dementia
533 Citations2004Vincenzo Solfrizzi, Francesco Panza +12 more
In this population, among those who progressed to dementia, 60% progressed to AD and 33% to VaD and there was a nonsignificant trend for stroke as a risk factor of progression of MCI to dementia.
Journal of Pharmacokinetics and BiopharmaceuticsBuilding population pharmacokineticpharmacodynamic models. I. Models for covariate effects
495 Citations1992Jaap W. Mandema, Davide Verotta +1 more
A previously described approach to efficiently find the relationships between the PK-PD parameters and covariates is extended and the time required to derive a population model is markedly reduced because the number of necessary NONMEM runs is reduced.
American Journal of PsychiatryA longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration
407 Citations1994Robert G. Stern, Richard C. Mohs +7 more
Cognitive deterioration is slow during the early and very late stages of Alzheimer's disease and more rapid during the middle stages, suggesting that treatment trials and attempts to identify subgroups are affected.
Archives of NeurologySex, Apolipoprotein E ε4 Status, and Hippocampal Volume in Mild Cognitive Impairment
256 Citations2005Adam Fleisher
The APOE*E4 genotype status appears to have a greater deleterious effect on gross hippocampal pathology and memory performance in women than in men.
NeurologyClinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment
232 Citations2007Adam Fleisher, B. Brooke Sowell +4 more
Progression from amnestic mild cognitive impairment to Alzheimer disease in this cohort was best determined by combining four common, easily administered, cognitive measures.
NeurologyAPOE ε4 allele predicts faster cognitive decline in mild Alzheimer disease
217 Citations2008Stephanie Cosentino, Nikolaos Scarmeas +6 more
APOE ε4 may influence rate of cognitive decline most significantly in the earliest stages of Alzheimer disease, particularly in the incident population-based AD group.
Dementia and Geriatric Cognitive DisordersAnnual Rate and Predictors of Conversion to Dementia in Subjects Presenting Mild Cognitive Impairment Criteria Defined according to a Population-Based Study
185 Citations2004Hélène Amieva, Luc Letenneur +8 more
The quite elevated conversion rates obtained show the usefulness, when defining MCI criteria, of considering not only memory impairment but also impairment in other cognitive areas, as well as mild impairment on higher-order activities of daily living.
Alzheimer s & DementiaDisease progression meta‐analysis model in Alzheimer's disease
184 Citations2009Kaori Ito, Sima Ahadieh +5 more
A model based on literature data was developed to describe the longitudinal response in the Alzheimer's Disease Assessment Scale‐Cognitive (ADAS‐cog) (change from baseline) in mild to moderate severity AD patients.
NeurologyVolumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment
183 Citations2008Adam Fleisher, Shichang Sun +7 more
In moderate stages of amnestic mild cognitive impairment, common cognitive tests provide better predictive accuracy than measures of whole brain, ventricular, entorhinal cortex, or hippocampal volumes for assessing progression to Alzheimer disease.
Pharmaceutical ResearchPopulation Pharmacokinetic Modeling: The Importance of Informative Graphics
176 Citations1995Ene Ette, Thomas M. Ludden
The findings suggest that using informative graphical and statistical techniques enhance the understanding of the data structure and lead to an efficient analysis of theData.
NeurologyRisk factors for transitions from normal to mild cognitive impairment and dementia
175 Citations2006Richard J. Kryscio, Frederick A. Schmitt +3 more
Aside from age, the usual risk factors associated with conversion from cognitively normal into dementia are likely risk factors for transitions into mild cognitive impairment.
Journal of Pharmacokinetics and BiopharmaceuticsA three-step approach combining bayesian regression and NONMEM population analysis: Application to midazolam
173 Citations1991P. Maitre, Michael Bührer +2 more
This method was used to analyze the pharmacokinetics of midazolam in 64 subjects from 714 plasma concentrations and 11 demographic factors, and found CL and V1 were found to be a function of body weight.
NeurologyThe Alzheimer's disease assessment scale
168 Citations1997P. Murali Doraiswamy, Florian Bieber +4 more
Examination of distribution of baseline ADAS-Cog scores in relation to selected demographic and clinical variables suggests age, gender, age at onset of dementia, level of education, and use of estrogen or anti-inflammatory drugs are related to cognitive abilities in AD.
The Annual Review of Pharmacology and ToxicologyDrug Treatment Effects on Disease Progression
162 Citations2001P Chan, NHG Holford
Degenerative disease progress models combined with pharmacokinetic pharmacodynamic models and hierarchical random effects statistical models provide insights into understanding the time course and management of degenerative disease.
Pharmacometrics : the science of quantitative pharmacology
153 Citations2007Ene Ette, Paul J. Williams
Reading online Pharmacometrics: The Science of Quantitative Pharmacology book will be provide using wonderful book reader and it's might gives you some access to identifying the book content before you download the book.
Elsevier eBooksPrinciples of Clinical Pharmacology
129 Citations2007Arthur J. Atkinson
The third edition ofciples of Clinical Pharmacology has been thoroughly updated to provide readers with an ideal reference covering the wide range of important topics impacting clinical pharmacology as the discipline plays an increasingly significant role in drug development and regulatory science.
Proceedings of the National Academy of SciencesMethodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.
89 Citations1992Nicholas H. G. Holford, Karl E. Peace
A population pharmacodynamic model has been developed that allows the use of all observations from one or more trials to be combined and can incorporate any sequence of active or placebo treatments and account for carryover effects of both placebo and active drug.
Current Psychiatry ReportsModeling the time-course of Alzheimer dementia
84 Citations2001J. Wesson Ashford, Frederick A. Schmitt
Clinicians and researchers can use TI quantification to assess dementia severity and initial therapy benefits, and rate of progression measures can be used to support diagnosis and to investigate disease-course-modifying therapies.
Archives of General PsychiatryInfluence of Cognitive Status, Age, and APOE-4 Genetic Risk on Brain FDDNP Positron-Emission Tomography Imaging in Persons Without Dementia
57 Citations2009Gary W. Small, Prabha Siddarth +11 more
Impaired cognitive status, older age, and APOE-4 carrier status are associated with increased brain FDDNP-PET binding in persons without dementia, consistent with previous clinical and postmortem studies associating these risk factors with amyloid plaque and tau tangle accumulation.
BMC NeurologyTo what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?
53 Citations2002J. Jaime, Alexandra Ward +5 more
In patients with mild-to-moderate Alzheimer's disease, even relatively small degrees of poorer cognitive function increased the risk of losing the ability to live independently.
Clinical Pharmacology & TherapeuticsUsing Disease Progression Models as a Tool to Detect Drug Effect
43 Citations2007Diane R. Mould, Nicholas G. Denman +1 more
Generally, information required for approval of new drugs is dichotomous in that the drug is either efficacious and safe or not, so providing answers to the more difficult question of how to use the drug in a clinical setting is essential.
Archives of Clinical NeuropsychologyBaseline cognitive function predicts rate of decline in basic-care abilities of individuals with dementia of the Alzheimer's type
40 Citations2006Timothy B. Atchison, Paul J. Massman +1 more
Patients showing rapid decline of PSM function displayed significantly more impaired performance on neuropsychological measures at diagnosis, and the pattern of the rapid declining group included more severe impairment in visual spatial skills, processing speed, and concept formation.